Mounting evidence indicates that high levels of tumor-associated macrophages (TAMs) [6,25,36,56], and especially CD163+ TAMs of the M2-like phenotype [34,37,38,39], are associated with poor prognosis in breast cancer. This evidence concerns the gene CD163 and breast carcinoma.